Rystiggo Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The rystiggo market research report is one of a series of new reports that provides rystiggo market statistics, including the rystiggo industry's global market size, regional shares, competitors with a rystiggo market share, detailed rystiggo market segments, market trends and opportunities, and any further data you may need to thrive in the rystiggo industry. This rystiggo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The growth in the forecast period can be attributed to the increasing prevalence of autoimmune diseases, rising demand for novel therapeutics, rising prevalence of myasthenia gravis, and increasing prevalence of multiple sclerosis. Major trends in the forecast period include modern advances in medical research and therapeutic innovations, development of novel therapies, development of novel therapeutics, telemedicine for managing MS, and advancement in targeted therapies.

The increasing prevalence of myasthenia gravis is expected to drive the growth of the Rystiggo market in the coming years. Myasthenia gravis (MG) is a chronic autoimmune disorder that affects the neuromuscular system, causing weakness in the skeletal muscles. The rising number of MG cases can be attributed to factors such as improved diagnosis, greater awareness, better reporting systems, an aging population, and longer life expectancy among affected individuals. Rystiggo (rozanolixizumab) is a monoclonal antibody designed to treat myasthenia gravis by targeting and inhibiting the neonatal Fc receptor (FcRn). For example, in February 2024, the National Institutes of Health reported that in 2021, approximately 82,715 adults in the United States were living with MG, with a prevalence rate of 320.2 cases per million people. This growing prevalence is a key driver for the expansion of the Rystiggo market.

The growth of the Rystiggo market is also expected to be fueled by rising healthcare expenditure. Healthcare expenditure refers to the overall spending on medical services, products, and public health initiatives. The increase in healthcare spending is largely driven by an aging population in need of more medical care and the rising prevalence of chronic diseases, including diabetes and heart conditions. Healthcare spending for Rystiggo includes medication costs, infusion services, monitoring, specialty pharmacies, and patient support programs for managing generalized myasthenia gravis. For instance, in November 2024, the Health Foundation reported that the UK’s Department of Health and Social Care plans to increase its daily spending, projecting a rise from approximately $219.5 billion (£177.9 billion) to $239.3 billion (£190.1 billion) in 2024/25, and further to $254.5 billion (£200.5 billion) in 2025/26. Therefore, the increase in healthcare expenditure is contributing to the market’s growth.

An important trend in the Rystiggo market is the development of innovative treatments for generalized myasthenia gravis. The focus is on addressing unmet medical needs, improving patient outcomes, and gaining a competitive advantage in the healthcare sector. Treatment options for generalized myasthenia gravis include acetylcholinesterase inhibitors, immunosuppressive therapies, targeted biological agents, and interventions such as plasma exchange or thymectomy to reduce autoantibody activity and enhance muscle strength. In June 2023, UCB Inc. received FDA approval for Rystiggo (rozanolixizumab-noli) as the first treatment specifically targeting adults with generalized myasthenia gravis who are positive for anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibodies. This approval followed promising results from the Phase 3 MycarinG study, which showed significant improvements in patients’ daily functioning. Rystiggo is administered via subcutaneous infusion once a week for six weeks, and its approval has been well received by patient advocacy groups, highlighting its potential to address significant unmet medical needs in the generalized myasthenia gravis community.

The key company operating in the rystiggo market is UCB Inc.

North America was the largest region in the rystiggo market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in rystiggo report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the rystiggo market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Rystiggo refers to rozanolixizumab-noli, a medication used to treat generalized myasthenia gravis (gMG) in adults. It is administered as a subcutaneous infusion and works by targeting the neonatal Fc receptor (FcRn) to reduce pathogenic IgG autoantibodies, which are involved in the condition.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main types of Rystiggo treatment include monotherapy and combination therapy. Monotherapy involves the use of a single drug or therapeutic agent to treat a disease, as opposed to combining multiple drugs. The primary clinical indications for Rystiggo include generalized myasthenia gravis (gMG) and, in some cases, autoimmune neurological disorders (off-label use). It is distributed through several channels, including hospitals, clinics, and diagnostic centers.

The rystiggo market consists of sales of products including efgartigimod alfa-fcab (Vyvgart), zilucoplan (Zilbrysq), and eculizumab (Soliris). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.